Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Proto Script Pharmaceutical's Days Payable or its related term are showing as below:
PSCR's Days Payable is not ranked *
in the Business Services industry.
Industry Median: 45.76 * Ranked among companies with meaningful Days Payable only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proto Script Pharmaceutical Days Payable vs Business Services Industry
For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Days Payable distribution charts can be found below:
* The bar in red indicates where Proto Script Pharmaceutical's Days Payable falls into.
Proto Script Pharmaceutical Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proto Script Pharmaceutical (PSCR) has a Days Payable of 379.41 as of Sep. 2017. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Proto Script Pharmaceutical and its competitors.
Is Proto Script Pharmaceutical's Days Payable too high?
Proto Script Pharmaceutical's current Days Payable is 379.41. The Business Services industry median Days Payable is 45.76. Proto Script Pharmaceutical's value of 379.41 is 729.1% above this industry median.
How does Proto Script Pharmaceutical's Days Payable compare to EXCC and NXES?
Proto Script Pharmaceutical's Days Payable of 379.41 can be compared against companies in the Business Services industry. The industry median Days Payable is 45.76. Proto Script Pharmaceutical's value of 379.41 is 729.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Business Services company?
The median Days Payable among Business Services companies is 45.76, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proto Script Pharmaceutical's current Days Payable of 379.41 is 729.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Proto Script Pharmaceutical and its competitors. For the Business Services industry, the median Days Payable is 45.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proto Script Pharmaceutical's current Days Payable is 379.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proto Script Pharmaceutical stock overvalued right now?
Proto Script Pharmaceutical (PSCR) has a current Days Payable of 379.41. The current Days Payable is 379.41 and 729.1% above the Business Services industry median of 45.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Proto Script Pharmaceutical (PSCR), the current Days Payable is 379.41 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSCR has been successfully added to your 
